Thalidomide in myelofibrosis with myeloid metaplasia

A pooled-analysis of individual patient data from five studies

Barosi Giovanni, Elliott Michelle, Canepa Letizia, Ballerini Filippo, Piccaluga Pier Paolo, Visani Giuseppe, Marchetti Monia, Pozzato Gabriele, Zorat Fancesca, Ayalew Tefferi

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Trials to determine the effect of thalidomide in patients with Myelofibrosis with Myeloid Metaplasia (MMM) have produced inconclusive results due to different criteria for response and heterogeneous study participants. We undertook a pooled-analysis to assess the effects of such treatment on a larger series of cases and with a uniform assessment of response. We used updated data on 62 individual patients from 5 phase II trials that evaluated thalidomide therapy in MMM patients. Response was judged on individual disease parameters, on the improvement of the Dupriez risk categories and on the improvement of a 6 point "severity score" based on myeloproliferative and myelodepletive indexes of the disease. Overall, using standard dose of thalidomide, i.e. starting with no less than 100 mg/day, 49 patients (79%) had more than 4 weeks of therapy. Twenty-nine percent of patients with moderate to severe anemia showed an increase in hemoglobin or reduction/abolishment of blood transfusion requirements, 38% with moderate to severe thrombocytopenia had an increase in platelet counts, and 41% with high grade splenomegaly demonstrated a measurable reduction in splenic size. These effects led to an absolute decrease in the "severity" score in 44.9% of the patients. Major disease severity and high degrees of splenomegaly before therapy predicted response with a probability of 61.9%. However, worsening of the "severity" score was observed in 20.4% of the patients, 18% having a "myeloproliferative reaction" with leukocytosis and/or thrombocytosis. Sixty-six percent of the patients discontinued the drug before 6 months of treatment due to intolerance. In conclusion, there is a small but clear improvement of disease severity with thalidomide therapy in MMM. The potential for myeloproliferative reactions and the unfavorable dose-related toxicity profile argue for future studies using lower doses of this drug.

Original languageEnglish (US)
Pages (from-to)2301-2307
Number of pages7
JournalLeukemia and Lymphoma
Volume43
Issue number12
DOIs
StatePublished - Dec 1 2002

Fingerprint

Primary Myelofibrosis
Thalidomide
Splenomegaly
Therapeutics
Thrombocytosis
Leukocytosis
Platelet Count
Blood Transfusion
Thrombocytopenia
Pharmaceutical Preparations
Anemia
Hemoglobins

Keywords

  • Myelofibrosis with myeloid metaplasia
  • Myeloproliferative reaction
  • Pooled-analysis
  • Splenomegaly
  • Thalidomide

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Thalidomide in myelofibrosis with myeloid metaplasia : A pooled-analysis of individual patient data from five studies. / Giovanni, Barosi; Michelle, Elliott; Letizia, Canepa; Filippo, Ballerini; Paolo, Piccaluga Pier; Giuseppe, Visani; Monia, Marchetti; Gabriele, Pozzato; Fancesca, Zorat; Tefferi, Ayalew.

In: Leukemia and Lymphoma, Vol. 43, No. 12, 01.12.2002, p. 2301-2307.

Research output: Contribution to journalArticle

Giovanni, B, Michelle, E, Letizia, C, Filippo, B, Paolo, PP, Giuseppe, V, Monia, M, Gabriele, P, Fancesca, Z & Tefferi, A 2002, 'Thalidomide in myelofibrosis with myeloid metaplasia: A pooled-analysis of individual patient data from five studies', Leukemia and Lymphoma, vol. 43, no. 12, pp. 2301-2307. https://doi.org/10.1080/1042819021000040008
Giovanni, Barosi ; Michelle, Elliott ; Letizia, Canepa ; Filippo, Ballerini ; Paolo, Piccaluga Pier ; Giuseppe, Visani ; Monia, Marchetti ; Gabriele, Pozzato ; Fancesca, Zorat ; Tefferi, Ayalew. / Thalidomide in myelofibrosis with myeloid metaplasia : A pooled-analysis of individual patient data from five studies. In: Leukemia and Lymphoma. 2002 ; Vol. 43, No. 12. pp. 2301-2307.
@article{900f6441308145ab920ea2486bdd015d,
title = "Thalidomide in myelofibrosis with myeloid metaplasia: A pooled-analysis of individual patient data from five studies",
abstract = "Trials to determine the effect of thalidomide in patients with Myelofibrosis with Myeloid Metaplasia (MMM) have produced inconclusive results due to different criteria for response and heterogeneous study participants. We undertook a pooled-analysis to assess the effects of such treatment on a larger series of cases and with a uniform assessment of response. We used updated data on 62 individual patients from 5 phase II trials that evaluated thalidomide therapy in MMM patients. Response was judged on individual disease parameters, on the improvement of the Dupriez risk categories and on the improvement of a 6 point {"}severity score{"} based on myeloproliferative and myelodepletive indexes of the disease. Overall, using standard dose of thalidomide, i.e. starting with no less than 100 mg/day, 49 patients (79{\%}) had more than 4 weeks of therapy. Twenty-nine percent of patients with moderate to severe anemia showed an increase in hemoglobin or reduction/abolishment of blood transfusion requirements, 38{\%} with moderate to severe thrombocytopenia had an increase in platelet counts, and 41{\%} with high grade splenomegaly demonstrated a measurable reduction in splenic size. These effects led to an absolute decrease in the {"}severity{"} score in 44.9{\%} of the patients. Major disease severity and high degrees of splenomegaly before therapy predicted response with a probability of 61.9{\%}. However, worsening of the {"}severity{"} score was observed in 20.4{\%} of the patients, 18{\%} having a {"}myeloproliferative reaction{"} with leukocytosis and/or thrombocytosis. Sixty-six percent of the patients discontinued the drug before 6 months of treatment due to intolerance. In conclusion, there is a small but clear improvement of disease severity with thalidomide therapy in MMM. The potential for myeloproliferative reactions and the unfavorable dose-related toxicity profile argue for future studies using lower doses of this drug.",
keywords = "Myelofibrosis with myeloid metaplasia, Myeloproliferative reaction, Pooled-analysis, Splenomegaly, Thalidomide",
author = "Barosi Giovanni and Elliott Michelle and Canepa Letizia and Ballerini Filippo and Paolo, {Piccaluga Pier} and Visani Giuseppe and Marchetti Monia and Pozzato Gabriele and Zorat Fancesca and Ayalew Tefferi",
year = "2002",
month = "12",
day = "1",
doi = "10.1080/1042819021000040008",
language = "English (US)",
volume = "43",
pages = "2301--2307",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Thalidomide in myelofibrosis with myeloid metaplasia

T2 - A pooled-analysis of individual patient data from five studies

AU - Giovanni, Barosi

AU - Michelle, Elliott

AU - Letizia, Canepa

AU - Filippo, Ballerini

AU - Paolo, Piccaluga Pier

AU - Giuseppe, Visani

AU - Monia, Marchetti

AU - Gabriele, Pozzato

AU - Fancesca, Zorat

AU - Tefferi, Ayalew

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Trials to determine the effect of thalidomide in patients with Myelofibrosis with Myeloid Metaplasia (MMM) have produced inconclusive results due to different criteria for response and heterogeneous study participants. We undertook a pooled-analysis to assess the effects of such treatment on a larger series of cases and with a uniform assessment of response. We used updated data on 62 individual patients from 5 phase II trials that evaluated thalidomide therapy in MMM patients. Response was judged on individual disease parameters, on the improvement of the Dupriez risk categories and on the improvement of a 6 point "severity score" based on myeloproliferative and myelodepletive indexes of the disease. Overall, using standard dose of thalidomide, i.e. starting with no less than 100 mg/day, 49 patients (79%) had more than 4 weeks of therapy. Twenty-nine percent of patients with moderate to severe anemia showed an increase in hemoglobin or reduction/abolishment of blood transfusion requirements, 38% with moderate to severe thrombocytopenia had an increase in platelet counts, and 41% with high grade splenomegaly demonstrated a measurable reduction in splenic size. These effects led to an absolute decrease in the "severity" score in 44.9% of the patients. Major disease severity and high degrees of splenomegaly before therapy predicted response with a probability of 61.9%. However, worsening of the "severity" score was observed in 20.4% of the patients, 18% having a "myeloproliferative reaction" with leukocytosis and/or thrombocytosis. Sixty-six percent of the patients discontinued the drug before 6 months of treatment due to intolerance. In conclusion, there is a small but clear improvement of disease severity with thalidomide therapy in MMM. The potential for myeloproliferative reactions and the unfavorable dose-related toxicity profile argue for future studies using lower doses of this drug.

AB - Trials to determine the effect of thalidomide in patients with Myelofibrosis with Myeloid Metaplasia (MMM) have produced inconclusive results due to different criteria for response and heterogeneous study participants. We undertook a pooled-analysis to assess the effects of such treatment on a larger series of cases and with a uniform assessment of response. We used updated data on 62 individual patients from 5 phase II trials that evaluated thalidomide therapy in MMM patients. Response was judged on individual disease parameters, on the improvement of the Dupriez risk categories and on the improvement of a 6 point "severity score" based on myeloproliferative and myelodepletive indexes of the disease. Overall, using standard dose of thalidomide, i.e. starting with no less than 100 mg/day, 49 patients (79%) had more than 4 weeks of therapy. Twenty-nine percent of patients with moderate to severe anemia showed an increase in hemoglobin or reduction/abolishment of blood transfusion requirements, 38% with moderate to severe thrombocytopenia had an increase in platelet counts, and 41% with high grade splenomegaly demonstrated a measurable reduction in splenic size. These effects led to an absolute decrease in the "severity" score in 44.9% of the patients. Major disease severity and high degrees of splenomegaly before therapy predicted response with a probability of 61.9%. However, worsening of the "severity" score was observed in 20.4% of the patients, 18% having a "myeloproliferative reaction" with leukocytosis and/or thrombocytosis. Sixty-six percent of the patients discontinued the drug before 6 months of treatment due to intolerance. In conclusion, there is a small but clear improvement of disease severity with thalidomide therapy in MMM. The potential for myeloproliferative reactions and the unfavorable dose-related toxicity profile argue for future studies using lower doses of this drug.

KW - Myelofibrosis with myeloid metaplasia

KW - Myeloproliferative reaction

KW - Pooled-analysis

KW - Splenomegaly

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=0036890863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036890863&partnerID=8YFLogxK

U2 - 10.1080/1042819021000040008

DO - 10.1080/1042819021000040008

M3 - Article

VL - 43

SP - 2301

EP - 2307

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 12

ER -